Anthracyclines, such as doxorubicin, represent one group of chemotherapy drugs with the
most cardiotoxicity. Despite that anthracyclines are capable of treating assorted solid tumors …

Cardiotoxic side-effects represent a serious complication of anticancer therapy with
anthracyclines, in particular with doxorubicin (DXR) being the leading drug of the group …

Doxorubicin (Adriamycin®) is a potent and broad-spectrum antineoplastic agent, the clinical
utility of which is restricted by a cumulative and progressive cardiomyopathy that develops …

Doxorubicin (DOX) has not only chronic, but also acute toxic effects in the heart, ascribed to
the generation of reactive oxygen species (ROS). Focusing on the DOX-induced early …

Doxorubicin and other anthracyclines are among the most potent chemotherapeutic drugs
for the treatment of acute leukaemia, lymphomas and different types of solid tumours such as …

Background. This study examined whether administration of l‐carnitine ameliorates
gentamicin‐induced renal injury in rats. Methods. Male Sprague–Dawley rats were assigned …

L-carnitine is a quaternary amine that is essential for the normal oxidation of long-chain fatty
acids by mitochondria. It is known that L-carnitine and its derivatives prevent the formation of …

The major limiting factor in long‐term administration of doxorubicin is the development of
cumulative dose‐dependent cardiomyopathy and congestive heart failure. Although several …

Cardiomyopathy induced by Adriamycin (ADR) is a cause of congestive heart failure.
Recently, it has been suggested that ADR inhibits the carnitine palmitoyltransferase system …

This study examined whether doxorubicin therapy alters the expression of heart fatty acid
binding protein (H-FABP) and organic cation/carnitine transporter (OCTN2) genes in cardiac …